Form 4: Arteris Director Sells Shares Under 10b5-1 Plan

Arteris, Inc. Director Saiyed Atiq Raza has reported the sale of common stock totaling over 70,000 shares through a pre-arranged 10b5-1 trading plan.

Summary

• Director Saiyed Atiq Raza executed a 10b5-1 trading plan on November 7, 2025, for the sale of Arteris, Inc. common stock.
• Transactions occurred on July 1, 2026, involving the sale of various amounts of common stock at weighted average prices ranging from $43.98 to $47.10.
• The total number of shares sold across these transactions is 70,000.
• The reporting person also reported holding 4,703 shares directly.
• The shares sold were held indirectly through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant sale of shares by a director, even though it was conducted under a 10b5-1 plan.

Negatives

• Director Saiyed Atiq Raza sold a significant number of shares (70,000) through a 10b5-1 plan.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which primarily reports past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan allows insiders to sell shares according to a pre-determined schedule or formula, which can help mitigate concerns about insider trading, especially during periods of significant stock price movement or before major company announcements.

Stakeholder Impact

• Shareholders may view the director's sale of stock as a potential signal of reduced confidence in the company's short-term prospects, despite the sale being executed under a pre-arranged plan.

Key Dates

Recommendation

The filing reports a director's sale of stock under a 10b5-1 plan. While insider selling can be a negative signal, the pre-arranged nature of the plan suggests it may be for personal financial planning rather than a reflection of negative company outlook. Without further context on the company's performance or the director's reasons, a 'hold' recommendation is prudent, advising investors to monitor future filings and company performance.

Keywords

Arteris, Inc., Form 4, SEC Filing, Insider Trading, 10b5-1 Plan, Stock Sale, Director Transaction, Beneficial Ownership